Tandem Diabetes Care's EBITDA per Share for the
three
months ended in Dec. 2023 was $-0.40.
During the past 3 years, the average EBITDA Per Share Growth Rate was -138.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Tandem Diabetes Care was 76.20% per year. The lowest was -138.30% per year. And the median was 31.90% per year.
Competitive Comparison
For the Medical Devices subindustry, Tandem Diabetes Care's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tandem Diabetes Care 5-Year EBITDA Growth Rate Distribution
For the Medical Devices & Instruments industry and Healthcare sector, Tandem Diabetes Care's 5-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Tandem Diabetes Care's 5-Year EBITDA Growth Rate falls into.
Tandem Diabetes Care 5-Year EBITDA Growth Rate Calculation
This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
Tandem Diabetes Care (NAS:TNDM) 5-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.
Tandem Diabetes Care 5-Year EBITDA Growth Rate Related Terms
Thank you for viewing the detailed overview of Tandem Diabetes Care's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Tandem Diabetes Care (Tandem Diabetes Care) Business Description
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. Nearly three quarters of total revenue is derived from the U.S., with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TNDM has been successfully added to your